MacroGenics MGNX Stock
MacroGenics Price Chart
MacroGenics MGNX Financial and Trading Overview
| MacroGenics stock price | 4.12 USD |
| Previous Close | 4.13 USD |
| Open | 4.12 USD |
| Bid | 2.92 USD x 200 |
| Ask | 5.13 USD x 200 |
| Day's Range | 4.09 - 4.17 USD |
| 52 Week Range | 1.29 - 5.08 USD |
| Volume | 873.94K USD |
| Avg. Volume | 829.6K USD |
| Market Cap | 263.72M USD |
| Beta (5Y Monthly) | 1.225 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.59 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8 USD |
MGNX Valuation Measures
| Enterprise Value | 125.51M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.8247817 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.5057425 |
| Price/Book (mrq) | 6.1424327 |
| Enterprise Value/Revenue | 0.717 |
| Enterprise Value/EBITDA | -3.901 |
Trading Information
MacroGenics Stock Price History
| Beta (5Y Monthly) | 1.225 |
| 52-Week Change | 139.30% |
| S&P500 52-Week Change | 14.29% |
| 52 Week High | 5.08 USD |
| 52 Week Low | 1.29 USD |
| 50-Day Moving Average | 4.1 USD |
| 200-Day Moving Average | 3.14 USD |
MGNX Share Statistics
| Avg. Volume (3 month) | 829.6K USD |
| Avg. Daily Volume (10-Days) | 460K USD |
| Shares Outstanding | 63.7M |
| Float | 56.42M |
| Short Ratio | 14.1 |
| % Held by Insiders | 3.48% |
| % Held by Institutions | 77.61% |
| Shares Short | 7.12M |
| Short % of Float | 11.58% |
| Short % of Shares Outstanding | 11.18% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -8.33% |
| Operating Margin (ttm) | -42.19% |
| Gross Margin | -0.74% |
| EBITDA Margin | -18.36% |
Management Effectiveness
| Return on Assets (ttm) | -8.052% |
| Return on Equity (ttm) | -225.84% |
Income Statement
| Revenue (ttm) | 175.14M USD |
| Revenue Per Share (ttm) | 2.76 USD |
| Quarterly Revenue Growth (yoy) | 378.00% |
| Gross Profit (ttm) | -1304000 USD |
| EBITDA | -32169000 USD |
| Net Income Avi to Common (ttm) | -101056000 USD |
| Diluted EPS (ttm) | -1.59 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 173.3M USD |
| Total Cash Per Share (mrq) | 2.72 USD |
| Total Debt (mrq) | 35.09M USD |
| Total Debt/Equity (mrq) | 81.85 USD |
| Current Ratio (mrq) | 2.956 |
| Book Value Per Share (mrq) | 0.674 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -63724000 USD |
| Levered Free Cash Flow (ttm) | -69411128 USD |
Profile of MacroGenics
| Country | United States |
| State | MD |
| City | Rockville |
| Address | 9704 Medical Center Drive |
| ZIP | 20850 |
| Phone | 301 251 5172 |
| Website | https://www.macrogenics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 293 |
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Q&A For MacroGenics Stock
What is a current MGNX stock price?
MacroGenics MGNX stock price today per share is 4.12 USD.
How to purchase MacroGenics stock?
You can buy MGNX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for MacroGenics?
The stock symbol or ticker of MacroGenics is MGNX.
Which industry does the MacroGenics company belong to?
The MacroGenics industry is Biotechnology.
How many shares does MacroGenics have in circulation?
The max supply of MacroGenics shares is 63.7M.
What is MacroGenics Price to Earnings Ratio (PE Ratio)?
MacroGenics PE Ratio is now.
What was MacroGenics earnings per share over the trailing 12 months (TTM)?
MacroGenics EPS is -1.59 USD over the trailing 12 months.
Which sector does the MacroGenics company belong to?
The MacroGenics sector is Healthcare.
MacroGenics MGNX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27122.09 USD — |
+2.26
|
7.86B USD — | 26707.42 USD — | 27183.93 USD — | — - | 7.86B USD — |
|
US Tech Biotechnology
NBI
US
|
7047.44 USD — |
+1.1
|
— — | 6961.65 USD — | 7080.14 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1323.55 USD — |
+0.88
|
— — | 1309.56 USD — | 1327.32 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
33499.66 USD — |
+2.27
|
— — | 32987.52 USD — | 33576.02 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
7700.35 USD — |
+1.1
|
— — | 7606.61 USD — | 7736.07 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
13333.67 USD — |
+2.28
|
— — | 13126.46 USD — | 13364.18 USD — | — - | — — |
- {{ link.label }} {{link}}
